ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a patent in France and the United Kingdom relating to the treatment and detection of multiple myeloma and ovarian cancer. Patent No. 1,204,683, entitled "Ovarian cancer cells and myeloma cell surface glycoproteins, antibodies thereto, and uses therof," covers aspects of the Company's monoclonal antibody ICT-69, which targets human multiple myeloma and ovarian cancer cells. ICT-69 is already covered in the United States and this patent expands coverage of Company's issued patent portfolio to nine.
"We are actively extending our intellectual property protection for the treatment and detection of cancers," said Manish Singh, Ph.D. president and CEO of ImmunoCellular Therapeutics. "Strengthening our patent portfolio will support the developmental efforts surrounding our technology platforms and enhance our ability to license or partner these platforms."
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer